title: Ceramide induces apoptosis to immature cerebellar granule cells in culture.
abstract: A recent study revealed that ceramide acts as a second messenger in the sphingomyelin pathway and thus plays an important regulatory role in programmed cell death (apoptosis) to cell the lines induced by tumor-necrosis factor (TNF)-alpha and interleukin (IL)-1beta, although its effect remains controversial regarding primary neuronal culture. We investigated the effect of a cell-permeable ceramide analog (C2-ceramide) on cultures of cerebellar granule cells, which is thought to have active sphingomyelin pathway during development. The presence of C2-ceramide decreased the number of cerebellar granule cells (CGCs) in a concentration-dependent manner when added at DIV 1 (1 day in vitro). The ED50 was 60 microM. After DIV 2, CGCs became less sensitive to C2-ceramide and the ED50 was 200 microM at DIV 7. DNA staining with Hoechst 33258 showed the morphology of apoptotic nuclei in the degenerating neurons. Internucleosomal DNA degradation could also be observed by gel electrophoresis. Protein and RNA synthesis inhibitors prevented the death of neurons. C2-dihydroceramide, which lacks the 4-5 trans double bond and failed to induce neuronal death. These results thus demonstrated that C2-ceramide induces apoptosis to the CGCs at the early stage in vitro, however the CGCs were found to be less sensitive to C2-ceramide at the later stage in vitro.
authors.affiliation: Department of Neurology, Neurological Institute, Faculty of Medicine, Kyushu University, Fukuoka, Japan. t_taniwa@neuro.med.kyushu-u.ac.jp
authors.forename: T
authors.initials: T
authors.lastname: Taniwaki
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: H
authors.initials: H
authors.lastname: Asahara
authors.forename: Y
authors.initials: Y
authors.lastname: Ohyagi
authors.forename: J
authors.initials: J
authors.lastname: Kira
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D002478:Cells, Cultured; D002518:Ceramides / Q000494:pharmacology*; D002531:Cerebellum / Q000166:cytology* / Q000187:drug effects; D003513:Cycloheximide / Q000494:pharmacology; D003609:Dactinomycin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D007375:Interleukin-1 / Q000494:pharmacology; D009474:Neurons / Q000166:cytology; D019384:Nucleic Acid Synthesis Inhibitors / Q000494:pharmacology; D014176:Protein Biosynthesis; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000096:biosynthesis; D051381:Rats; D017207:Rats, Sprague-Dawley; D013110:Sphingosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D013997:Time Factors; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D002518:Ceramides; D007375:Interleukin-1; C064769:N-acetylsphingosine; D019384:Nucleic Acid Synthesis Inhibitors; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D003609:Dactinomycin; D003513:Cycloheximide; D013110:Sphingosine